Updated:
Nyxoah
Nyxoah was established in 2009 by Olivier Taelman alongside a founding team with deep experience in neuromodulation, aiming to solve a persistent...
Nyxoah
Nyxoah was established in 2009 by Olivier Taelman alongside a founding team with deep experience in neuromodulation, aiming to solve a persistent compliance crisis in sleep medicine. Obstructive sleep apnea affects roughly one billion people globally, but the standard-of-care positive-airway-pressure mask records adherence rates below 50% at 12 months. The firm's Genio bilateral hypoglossal nerve stimulation system is designed as a fully implantable, leadless, battery-powered alternative that patients activate externally before sleep. A 2019 European IPO provided capital to scale manufacturing and clinical evidence, with a subsequent 2020 Nasdaq listing broadening the US investor base. The Genio system has received CE Mark clearance in Europe and is distributed in key markets including Germany, Switzerland, and the UK, where reimbursement pathways in public-health systems are being established country by country. Nyxoah's DREAM US pivotal study completed enrollment in 2023, evaluating Genio against a sham control in a randomized withdrawal design. The firm also runs a post-market registry tracking real-world patient adherence and apnea-hypopnea index reduction. Manufacturing takes place in Belgium, and the supply chain relies on specialized implantable-grade components sourced from European and Israeli medtech suppliers. Beyond the DREAM study, Nyxoah initiated the ACCCESS trial in 2023 for complete concentric collapse patients previously contraindicated for hypoglossal stimulation, potentially expanding the addressable market by 30-40%. The company reported €1.8 million in third-quarter 2024 revenue, reflecting early German hospital tenders and increasing implant volumes. External collaborators have included academic sleep centers such as Charité Berlin and clinical investigators who previously worked on the Inspire Medical Systems trials, creating a cross-pollinated researcher network. Nyxoah has not disclosed any philanthropic or family-office backing, operating purely as a venture-backed then publicly funded commercial-stage company. Nyxoah's structural differentiator is the Genio implant's external activation patch, which eliminates the need for a surgical pocket for an internal battery-communication module—the approach taken by its main competitor. This design shortens operating time, improves MRI compatibility, and allows future device upgrades without explant surgery. The dual-listing structure on Euronext and Nasdaq also provides a capital-markets pipeline distinct from the venture-private-equity route, with regulatory catalysts dictating liquidity windows rather than fund-life cycles.
General information
Firm type
Unclassified
Year founded
2009
AUM
Undisclosed
Location
Region
Europe
Country
Belgium
City
Mont-Saint-Guibert
Corporate office
Mont-Saint-Guibert, Belgium
Principals
Olivier Taelman
Chief Executive Officer
Sector focus
Frequently asked questions
How does Nyxoah's Genio system work, and what differentiates it from Inspire Medical's implant?
Genio stimulates the hypoglossal nerve to prevent airway collapse during sleep, similar in aim to Inspire. The key difference is the power source: Genio uses a disposable external activation patch that adheres to the chin, wirelessly powering the implanted microstimulator. This avoids a chest-pocket battery and allows the implant itself to be leadless and MRI-conditional up to 3 Tesla. Nyxoah argues this design reduces surgical time and may improve future-proofing, as upgrades to the external component do not require revision surgery.
What regulatory clearances does Nyxoah hold, and where is the product sold?
Genio holds CE Mark under the European Medical Device Regulation for bilateral hypoglossal nerve stimulation. Commercial sales have begun in Germany, Switzerland, and the United Kingdom, with market access expanding as individual hospital tenders and reimbursement codes are secured. The US FDA pathway is in progress through the DREAM pivotal study, with potential PMA submission timelines guided by the pace of data readout.
What is Nyxoah's financial profile and funding structure?
Nyxoah is a publicly traded company listed on Euronext Brussels (NYXH) and Nasdaq (NYXH). The firm does not operate as a family office, asset manager, or investment entity—it is a commercial-stage medical-device company that raises capital through public equity offerings. Reported third-quarter 2024 revenue stood at €1.8 million, reflecting the early stages of European commercialization. Historical funding prior to IPO included venture capital from Belgian and European life-sciences investors.
Who are Nyxoah's main institutional investors and are there any family-office backers?
The shareholder register is predominantly composed of European and American public-market institutional investors, including life-sciences specialist funds and cross-over investors who participated in the Nasdaq listing. No single-family office or multi-family office has been disclosed as a material backer. The firm's capital structure is entirely corporate rather than capital-pool-allocated, meaning a family-office due-diligence framework is not applicable here.
What is the ACCCESS trial and why is it significant?
The ACCCESS pivotal study targets patients with complete concentric collapse of the soft palate, a phenotype that historically has been a contraindication for hypoglossal nerve stimulation because the airway collapse pattern was considered untreatable. Nyxoah believes Genio's bilateral stimulation capability can address this anatomy, potentially expanding the treatable population by 30-40% beyond what existing devices cover. The first US implant occurred in January 2025, per the firm's public disclosures.
Why would a family-office allocator encounter Nyxoah in deal flow?
A family-office allocator would not encounter Nyxoah as a fund investment, because Nyxoah is not an asset manager or family office—it does not accept outside capital commitments. Nyxoah may appear in direct-public-equity or pre-IPO allocation pipelines, or as a co-investment opportunity during capital raises, but the firm itself is an operating company, not a capital allocator.
Is Nyxoah backed by a single-family office wealth origin?
No. As a Belgian medical-device company founded in 2009 and listed publicly since 2019, Nyxoah has no disclosed single-family-office wealth origin. The Altss profile format is designed for family offices and allocators; Nyxoah was captured in the research due to name-matching but fits the medical-device corporate archetype, not the family-capital structure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: